Mylod%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520at

# Mylot%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520at ## Overview Mylot%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520at is a brand name for a medication containing the active ingredient **Mephentermine Sulfate**. It is a sympathomimetic amine with predominantly alpha-adrenergic agonist activity, leading to vasoconstriction and increased peripheral vascular resistance. It also possesses some beta-adrenergic activity, which can result in cardiac stimulation. ## Primary Indications * **Hypotension:** Primarily used to treat hypotension associated with anesthesia (e.g., spinal anesthesia) or other causes where vasopressor support is needed. ## Adult Dosing * **Intravenous (IV):** * For acute hypotension during anesthesia: 10 mg to 30 mg IV. The dose can be repeated as needed. * For maintenance of blood pressure: 30 mg to 50 mg added to 500 mL of D5W or normal saline for continuous infusion. The infusion rate is titrated to maintain the desired blood pressure. * **Intramuscular (IM)/Subcutaneous (SC):** 5 mg to 20 mg IM or SC. This route is less commonly used due to the availability of IV administration and potential for slower onset. Maximum dose is not well-defined and depends on clinical response and patient factors. ## Pediatric Dosing Specific pediatric dosing for Mylot%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520at is not well-established. Dosing should be based on institutional protocols and individual patient response, often extrapolated from adult data with appropriate caution and lower initial doses. ## Dose Adjustments * **Renal Impairment:** No specific dose adjustments are typically provided, but caution is advised due to potential for accumulation. * **Hepatic Impairment:** No specific dose adjustments are typically provided, but caution is advised as the drug is metabolized in the liver. ## Contraindications * Known hypersensitivity to mephentermine. * Use with MAO inhibitors or within 14 days of discontinuing MAO inhibitors due to risk of hypertensive crisis. * Severe hypertension. ## Adverse Effects * **Cardiovascular:** Hypertension, tachycardia, palpitations, arrhythmias, chest pain. * **Central Nervous System:** Anxiety, dizziness, headache, tremors, nervousness, insomnia. * **Other:** Nausea, vomiting, dysuria, blurred vision. ## Key Drug Interactions * **Monoamine Oxidase Inhibitors (MAOIs):** Potentiates hypertensive effects, potentially leading to hypertensive crisis. Avoid concurrent use and for 14 days after MAOI discontinuation. * **Anesthetics (inhalational):** May potentiate cardiac arrhythmias. * **Beta-blockers:** May potentiate alpha-agonist effects of mephentermine, leading to severe hypertension. * **Guanethidine, Reserpine:** May decrease the pressor effect of mephentermine. ## Monitoring * **Blood Pressure:** Frequent monitoring of systolic and diastolic blood pressure is essential during and after administration. * **Heart Rate and Rhythm:** Monitor for tachycardia, arrhythmias. * **Urine Output:** Monitor for adequate renal perfusion. * **Central Venous Pressure (CVP):** May be helpful in assessing fluid status and cardiac filling pressures, especially in critically ill patients. ## Clinical Pearls * Mephentermine is a direct-acting sympathomimetic amine, primarily used for short-term management of hypotension. * Its use is often limited to perioperative settings where rapid onset and titration are needed. * Due to potential for arrhythmias and severe hypertension, careful patient selection and continuous monitoring are paramount. * Ensure adequate hydration before and during administration, as mephentermine may reduce renal blood flow. *** *This information is intended for healthcare professionals. Please consult the most current prescribing information and relevant clinical guidelines for complete details. Dosing may vary based on individual patient factors and local protocols.*